Use of real-world evidence for oncology clinical decision making in emerging economies

被引:12
|
作者
Petracci, Fernando [1 ]
Ghai, Chirag [2 ]
Pangilinan, Andrew [2 ]
Suarez, Luis Alberto [3 ]
Uehara, Roberto [4 ]
Ghosn, Marwan [5 ,6 ]
机构
[1] Inst Alexander Fleming, Breast Canc Dept, Ave Cramer 1180, RA-1426 Buenos Aires, Argentina
[2] Real World Evidence Strategy & Solut, IQVIA, New York, NY 10282 USA
[3] Pfizer Inc, B1607EEV, Buenos Aires, DF, Argentina
[4] Pfizer Inc, New York, NY 10017 USA
[5] France Univ Hosp, Hotel Dieu, Hematol & Oncol Dept, Beirut, Lebanon
[6] St Joseph Univ, Beirut, Lebanon
关键词
Asia-Pacific; effectiveness; electronic database; health policy; Latin America; Middle East; randomized clinical trials; real-world data; real-world evidence; safety; RENAL-CELL CARCINOMA; CANCER-PATIENTS; SUNITINIB; PROGRESSION; RESISTANCE; EFFICACY; THERAPY; TRIALS; SAFETY; HEALTH;
D O I
10.2217/fon-2021-0425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Traditionally, randomized clinical trials have been used to provide insights on new medical therapies and continue to remain the gold standard for approval. The-increasing availability of patient level data in the real-world, it is now possible to generate evidence regarding the usage and potential benefits or risks of a medical therapy derived from analysis of real-world data. This evidence is collectively referred to real-world evidence (RWE). randomized clinical trials and RWE are complementary and the area of Oncology especially benefits from RWE to guide clinical decision making across the patient journey. Key benefits include cancer screening and diagnosis, optimal treatment choices (including personalized medicine) and disease management such as dosing and treatment of side effects. In recent times, RWE generation in oncology has been prolific in the USA and western Europe. With expansive biopharmaceutical investments into infrastructure harnessing patient-level data and greater local regulatory guidance, oncology patients in emerging economies may now also have the opportunity to benefit from clinical decision making informed by RWE. Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.
引用
收藏
页码:2951 / 2960
页数:10
相关论文
共 50 条
  • [31] The Expanding Role of Real-World Evidence Trials in Health Care Decision Making
    Klonoff, David C.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (01): : 174 - 179
  • [32] Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence
    Caccialanza, Riccardo
    Goldwasser, Francois
    Marschal, Oliver
    Ottery, Faith
    Schiefke, Ingolf
    Tilleul, Patrick
    Zalcman, Gerard
    Pedrazzoli, Paolo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [33] Treatment sequencing in oncology: balancing clinical trial and real-world evidence Foreword
    Caffo, Orazio
    FUTURE ONCOLOGY, 2019, 15 (25) : 2887 - 2889
  • [34] Real-world evidence for regulatory decision-making: updated guidance from around the world
    Burns, Leah
    Le Roux, Nadege
    Kalesnik-Orszulak, Robert
    Christian, Jennifer
    Dudinak, Jennifer
    Rockhold, Frank
    Khozin, Sean
    O'Donnell, John
    FRONTIERS IN MEDICINE, 2023, 10
  • [35] Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone, Daniel C.
    Brown, Mary
    Hurwitz, Jason T.
    Peters, Loretta
    Graff, Jennifer S.
    VALUE IN HEALTH, 2018, 21 (03) : 326 - 333
  • [36] Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making
    Franklin, Jessica M.
    Glynn, Robert J.
    Martin, David
    Schneeweiss, Sebastian
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (04) : 867 - 877
  • [37] Use of real-world evidence for healthcare decision-making in the Middle East: practical considerations and future directions
    Akhras, Kasem S.
    Alsheikh-Ali, Alawi A.
    Kabbani, Samer
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (03) : 245 - 250
  • [38] Organic generation of real-world real-time data for clinical evidence in radiation oncology
    Bertolet, A.
    Wals, A.
    Miras, H.
    Macias, J.
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2020, 144
  • [39] Using real-world evidence (RWE) in regulatory decision making: A study of 6 oncology approvals with RWE included in the product label
    Zong, Jihong
    Jiao, Xiaolong
    Pan, Lucy
    Castelo, Sarah
    Campbell, Chelsey
    Lennert, Barb
    Bruno, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Smog, Cognition and Real-World Decision-Making
    Chen, Xi
    INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2019, 8 (02): : 76 - 80